VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

28 фев 2023 07:00:03 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day

26 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

12 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Host R&D Event on January 26, 2023

05 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

01 дек 2022 15:05:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

22 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

03 ноя 2022 15:01:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

27 окт 2022 15:05:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

27 окт 2022 08:00:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

19 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

29 авг 2022 15:05:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

15 авг 2022 15:05:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

15 авг 2022 15:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

11 авг 2022 15:05:03 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

29 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

01 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

12 май 2022 15:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer

09 май 2022 07:00:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

05 май 2022 15:05:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress

23 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire